Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 1994Journal of Magnetic Resonance Imaging

Phase I clinical evaluation of a new iron oxide MR contrast agent

View Full Paper
Ask AI
Bookmark
Share

Authors

SMStuart J. McLachlanPrinceton UniversityMMMarie R. MorrisEmory UniversityMLMaria A. LucasMiami University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

McLachlan et al. (1994) studied this question.

synapsesocial.com/papers/6a63b23c84b804377828dd6ehttps://doi.org/10.1002/jmri.1880040313
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging.1990 · 496 citations
  2. 2Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging.1990 · 1,038 citations
  3. 3Detection of liver metastases with superparamagnetic iron oxide in 15 patients: results of MR imaging at 1.5 T1989 · 122 citations
  4. 4Receptor imaging: application to MR imaging of liver cancer.1990 · 91 citations
  5. 5Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging.1992 · 188 citations